Anti-vascular endothelial growth factor therapy in retinopathy of prematurity: An updated literature review

Laser photocoagulation can still be considered the gold standard for treatment for retinopathy of prematurity (ROP). However, anti-vascular endothelial growth factor (anti-VEGF) therapy has increasingly become an important option that plays a significant role in the treatment of ROP. Major clinical...

Full description

Saved in:
Bibliographic Details
Published in:Saudi journal of ophthalmology 2022-07, Vol.36 (3), p.260-269
Main Authors: Alzuabi, Asma, Alshammari, Ola, Almousa, Abdullah, Abouammoh, Marwan
Format: Article
Language:English
Subjects:
Update on Retinopathy of Prematurity
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Laser photocoagulation can still be considered the gold standard for treatment for retinopathy of prematurity (ROP). However, anti-vascular endothelial growth factor (anti-VEGF) therapy has increasingly become an important option that plays a significant role in the treatment of ROP. Major clinical trials have been published regarding the anti-VEGF use in ROP, along with multiple other studies looking into the different agents, doses, techniques, and possible complications. Anti-VEGF therapies can be considered as a safe and effective option for managing ROP. More longitudinal randomized clinical trials are necessary to evaluate the preferred treatment agent, the appropriate dose, best follow-up protocol, and the long-term ocular and systemic outcomes following treatment.
ISSN:1319-4534
2542-6680
DOI:10.4103/sjopt.sjopt_12_22